

Martin W Hoyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/284113/publications.pdf>

Version: 2024-02-01

35
papers

1,252
citations

394421

19
h-index

377865

34
g-index

36
all docs

36
docs citations

36
times ranked

1826
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Medical Research Methodology, 2011, 11, 139.	3.1	233
2	T Helper Cell Type 2 Responsiveness Predicts Future Susceptibility to Gastrointestinal Nematodes in Humans. Journal of Infectious Diseases, 2004, 190, 1804-1811.	4.0	110
3	A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technology Assessment, 2014, 18, 1-406.	2.8	98
4	Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age and Ageing, 2013, 42, 14-20.	1.6	82
5	EFFECT OF POLLINATOR ABUNDANCE ON SELF-FERTILIZATION AND GENE FLOW: APPLICATION TO GM CANOLA. Ecological Applications, 2007, 17, 2123-2135.	3.8	53
6	Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma. Value in Health, 2010, 13, 61-68.	0.3	52
7	Causes of the species-area relationship by trophic level in a field-based microecosystem. Proceedings of the Royal Society B: Biological Sciences, 2004, 271, 1159-1164.	2.6	49
8	Future Drug Prices and Cost-Effectiveness Analyses. Pharmacoeconomics, 2008, 26, 589-602.	3.3	45
9	Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis. Pharmacoeconomics, 2011, 29, 1-15.	3.3	42
10	Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technology Assessment, 2016, 20, 1-594.	2.8	42
11	A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer, 2015, 15, 313.	2.6	37
12	Species richness of moss landscapes unaffected by short-term fragmentation. Oikos, 2004, 105, 359-367.	2.7	36
13	Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer. Value in Health, 2013, 16, 288-296.	0.3	36
14	Global Warming, Human Population Pressure, and Viability of the World's Smallest Butterfly. Conservation Biology, 2005, 19, 1113-1124.	4.7	35
15	THE EFFECT OF WIND DIRECTION ON CROSS-POLLINATION IN WIND-POLLINATED GM CROPS. , 2007, 17, 1234-1243.		34
16	Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia. Value in Health, 2011, 14, 1057-1067.	0.3	29
17	Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts. Medical Decision Making, 2010, 30, 426-437.	2.4	27
18	The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-294.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma. Value in Health, 2010, 13, 55-60.	0.3	22
20	Mixed effects of habitat fragmentation on species richness and community structure in a microarthropod microecosystem. Ecological Entomology, 2005, 30, 684-691.	2.2	21
21	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-326.	2.8	21
22	Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Pharmacoeconomics, 2018, 36, 837-851.	3.3	18
23	The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 1-588.	2.8	15
24	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 2018, 16, 429-432.	2.1	12
25	Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia. Pharmacoeconomics, 2022, 40, 807-821.	3.3	12
26	Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-Effectiveness Analyses. Value in Health, 2010, 13, 885-892.	0.3	11
27	A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow. Journal of Theoretical Biology, 2007, 248, 154-163.	1.7	9
28	When corridors work: Insights from a microecosystem. Ecological Modelling, 2007, 202, 441-453.	2.5	9
29	Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-226.	2.8	8
30	Maximum feasible distance of windborne cross-pollination in Brassica napus: A mass budget model. Ecological Modelling, 2009, 220, 1090-1097.	2.5	7
31	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2021, 25, 1-248.	2.8	7
32	Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30% Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 363-373.	3.3	6
33	Experimentally fragmented communities are more aggregated. Journal of Animal Ecology, 2005, 74, 430-442.	2.8	5
34	EVOLUTION OF A COST-UTILITY MODEL OF DONEPEZIL FOR ALZHEIMER'S DISEASE. International Journal of Technology Assessment in Health Care, 2013, 29, 147-154.	0.5	4
35	Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 39-49.	3.3	1